BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12481422)

  • 1. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts.
    Kawakami M; Kawakami K; Puri RK
    Mol Cancer Ther; 2002 Oct; 1(12):999-1007. PubMed ID: 12481422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways.
    Kawakami M; Kawakami K; Puri RK
    Int J Cancer; 2003 Jan; 103(1):45-52. PubMed ID: 12455052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells.
    Kawakami M; Kawakami K; Puri RK
    Cancer Immunol Immunother; 2002 Feb; 50(12):691-700. PubMed ID: 11862421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
    Husain SR; Puri RK
    J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
    Han J; Yang L; Puri RK
    J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.
    Mintz A; Gibo DM; Madhankumar AB; Debinski W
    J Neurooncol; 2003; 64(1-2):117-23. PubMed ID: 12952292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
    Kioi M; Kawakami K; Puri RK
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model.
    Kawakami K; Kawakami M; Puri RK
    Clin Cancer Res; 2004 Aug; 10(15):5264-70. PubMed ID: 15297430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
    Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
    Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
    Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK
    J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
    Kioi M; Husain SR; Croteau D; Kunwar S; Puri RK
    Technol Cancer Res Treat; 2006 Jun; 5(3):239-50. PubMed ID: 16700620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
    Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
    Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease.
    Kawakami K; Kawakami M; Puri RK
    Mol Cancer Ther; 2004 Feb; 3(2):137-47. PubMed ID: 14985454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer.
    Kawakami K; Kawakami M; Puri RK
    J Immunol; 2002 Dec; 169(12):7119-26. PubMed ID: 12471149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
    Kawakami K; Kawakami M; Joshi BH; Puri RK
    Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
    Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
    J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts.
    Kawakami K; Husain SR; Bright RK; Puri RK
    Cancer Gene Ther; 2001 Nov; 8(11):861-8. PubMed ID: 11773976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol-induced apoptotic death in human U251 glioma cells.
    Jiang H; Zhang L; Kuo J; Kuo K; Gautam SC; Groc L; Rodriguez AI; Koubi D; Hunter TJ; Corcoran GB; Seidman MD; Levine RA
    Mol Cancer Ther; 2005 Apr; 4(4):554-61. PubMed ID: 15827328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo.
    Kawakami K; Kawakami M; Husain SR; Puri RK
    Gene Ther; 2003 Jul; 10(13):1116-28. PubMed ID: 12808442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.
    Kawakami K; Husain SR; Kawakami M; Puri RK
    Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.